Ipsen, BioMérieux Partner on Theranostics Approach to Cancer
February 25, 2011
Ipsen, BioMérieux Partner on Theranostics Approach to Cancer
The collaboration will leverage Ipsen's broad portfolio of compounds and BioMérieux's diagnostic tests and focus on prostate and breast cancers, neuroendocrine tumors, and pituitary tomors.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- ASU's Biodesign Institute Wins $30M DoD Contract for Immunosignature-Based Pathogen Detection Chip
April 27, 2012 / ProteoMonitor - Cenix, Debiopharm Ink Biomarker ID Deal
May 23, 2013 / GenomeWeb Daily News - Industry Observers Question Myriad's Competitive Advantage as It Looks to Launch NGS Cancer Panel
May 22, 2013 / Clinical Sequencing News - KineMed, MedImmune Studying Role of Protein Dynamics in Neurodegenerative Diseases
May 21, 2013 / GenomeWeb Daily News - Personal Genome Diagnostics, Blueprint Medicines to ID Novel Drug Targets in Cancer
May 21, 2013 / GenomeWeb Daily News